Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
3 August 2020 |
Main ID: |
EUCTR2013-001150-10-GB |
Date of registration:
|
25/07/2013 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
STUDY OF ECULIZUMAB IN RELAPSING NEUROMYELITIS OPTICA SUBJECTS
|
Scientific title:
|
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN PATIENTS WITH RELAPSING NEUROMYELITIS OPTICA (NMO) |
Date of first enrolment:
|
18/02/2014 |
Target sample size:
|
132 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-001150-10 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: yes Other: no Number of treatment arms in the trial: 2
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Argentina
|
Australia
|
Austria
|
Belgium
|
Brazil
|
Canada
|
Colombia
|
Croatia
|
Czech Republic
|
Denmark
|
France
|
Germany
|
Hong Kong
|
Italy
|
Japan
|
Korea, Republic of
|
Peru
|
Russian Federation
|
Singapore
|
Spain
|
Sweden
|
Switzerland
|
Taiwan
|
Thailand
|
Turkey
|
United Kingdom
|
United States
| | | | | |
Contacts
|
Name:
|
European Clinical Trial Information
|
Address:
|
1-15 avenue Edouard Belin
92500
Rueil-Malmaison
France |
Telephone:
|
+33147 10 0606 |
Email:
|
clinicaltrials.eu@alxn.com |
Affiliation:
|
ALEXION EUROPE SAS |
|
Name:
|
European Clinical Trial Information
|
Address:
|
1-15 avenue Edouard Belin
92500
Rueil-Malmaison
France |
Telephone:
|
+33147 10 0606 |
Email:
|
clinicaltrials.eu@alxn.com |
Affiliation:
|
ALEXION EUROPE SAS |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: - Male or female patient = 18 years old
- Diagnosis of NMO or NMO spectrum disorder
- NMO-IgG seropositive
- Historical Relapse of at least 2 relapses in the last 12 months or 3 relapses in the last 24 months, with at least 1 relapse in the 12 months prior to the Screening
- EDSS score =7
- Immunosuppressive therapy is allowed provided patients have been on a stable maintenance dose prior to the Screening and remain on a stable dose for the duration of the study
- Patients must be willing and able to give written informed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 119 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 13
Exclusion criteria: - Use of rituximab or mitoxantrone within 3 months prior to Screening
- Use of IVIg within 3 weeks prior to screening
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Neuromyelitis Optica MedDRA version: 19.0
Level: LLT
Classification code 10029322
Term: Neuromyelitis optica
System Organ Class: 100000004852
|
Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
|
Intervention(s)
|
Trade Name: SOLIRIS Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ECULIZUMAB CAS Number: 219685-50-4 Current Sponsor code: h5G1.1-mAb Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use
|
Primary Outcome(s)
|
Main Objective: Efficacy of eculizumab treatment as compared with placebo in relapsing NMO patients based on the time to first relapse and relapse risk reduction.
|
Secondary Objective: - Safety and tolerability of eculizumab compared with placebo - Efficacy of eculizumab compared with placebo - Describe the pharmacokinetics (PK) and pharmacodynamics (PD) of eculizumab
|
Timepoint(s) of evaluation of this end point: Relapse evaluation visits: - Within 24/48 hours after relapse - Week +1 after relapse - Week +4 after relapse - Week +6 after relapse
Completion of the trial after 24 adjudicated On-Trial Relapse events in 24 distinct patients.
|
Primary end point(s): Time to first adjudicated On-Trial Relapse
|
Secondary Outcome(s)
|
Timepoint(s) of evaluation of this end point: evaluation at:
- Screening visit
- Weeks 1, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 104
- Relapse evaluation visits
- End of trial visit
|
Secondary end point(s): - Change from baseline in EDSS score at the End of Study Period
- Adjudicated annualized relapse rate
- Change from baseline in EQ-5D at the End of the Study Period
- Change from baseline in modified Rankin Scale (mRS) score at the End of the Study Period
- Change from baseline in ambulatory function as measured by Hauser Ambulation Index at the End of the Study Period.
|
Secondary ID(s)
|
2013-001150-10-DE
|
ECU-NMO-301
|
NCT01892345
|
Source(s) of Monetary Support
|
ALEXION PHARMACEUTICALS INC
|
Ethics review
|
Status: Approved
Approval date: 18/02/2014
Contact:
|
|